These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 8092908

  • 1. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction.
    Cody RJ.
    Arch Intern Med; 1994 Sep 26; 154(18):2029-36. PubMed ID: 8092908
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 26; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
    Mazzotta G, Vecchio C.
    G Ital Cardiol; 1994 Jan 26; 24(1):59-70. PubMed ID: 8200499
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
    Young JB.
    Cardiol Clin; 1995 Aug 26; 13(3):379-90. PubMed ID: 7585774
    [Abstract] [Full Text] [Related]

  • 5. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ, Lamas GA, Gordon D, Bernstein V, Pfeffer MA, Survival and Ventricular Enlargement Trial.
    Am Heart J; 2004 Aug 26; 148(2):356-64. PubMed ID: 15309009
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin converting enzyme inhibition therapy following myocardial infarction. Rationale for clinical trials.
    Pfeffer MA.
    Herz; 1991 Sep 26; 16 Spec No 1():278-82. PubMed ID: 1840297
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction.
    Linn WD.
    Pharmacotherapy; 1996 Sep 26; 16(2 Pt 2):50S-58S. PubMed ID: 8668606
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

  • 9. Postmyocardial infarction patients: experience from the SAVE trial.
    Connors KF, Lamas GA.
    Am J Crit Care; 1995 Jan 10; 4(1):23-8. PubMed ID: 7894551
    [Abstract] [Full Text] [Related]

  • 10. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 10; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 11. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 12. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C, Cosentino E, De Sanctis D.
    Ital Heart J Suppl; 2005 Dec 15; 6(12):769-79. PubMed ID: 16444921
    [Abstract] [Full Text] [Related]

  • 13. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 15; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 14. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov 15; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 15. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R, Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators.
    Arch Intern Med; 2006 Mar 27; 166(6):659-66. PubMed ID: 16567606
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitors in congestive heart failure.
    Deedwania PC.
    Arch Intern Med; 1990 Sep 27; 150(9):1798-805. PubMed ID: 2132302
    [Abstract] [Full Text] [Related]

  • 17. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 27; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 18. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, HOPE Investigators.
    Circulation; 2004 Sep 14; 110(11):1413-7. PubMed ID: 15353497
    [Abstract] [Full Text] [Related]

  • 19. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
    Pfeffer MA.
    Herz; 1993 Dec 14; 18 Suppl 1():430-5. PubMed ID: 8125423
    [Abstract] [Full Text] [Related]

  • 20. [ACE inhibitors in the treatment of patients with acute myocardial infarct].
    Borghi C, Ambrosioni E.
    Ann Ital Med Int; 1995 Dec 14; 10(3):175-87. PubMed ID: 7577315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.